Adam N. is an accomplished pharmacology and novel sciences expert currently serving as Group Head at Septerna, focusing on small molecule drug discovery. With extensive experience leading drug development programs across various companies, including 23andMe and Denali Therapeutics, Adam has developed expertise in target identification, pharmacology strategy, and assay development. A subject matter expert in multiple disease indications, Adam has successfully managed cross-functional teams, driving projects from target identification to medicine optimization while utilizing innovative genetic techniques and high-throughput screening methods. Adam holds a Ph.D. in Cancer Molecular Biology and Epidemiology from the University of Cambridge and a Bachelor's Degree in Biochemistry from Imperial College London.
This person is not in any teams
This person is not in any offices